We, and others, have previously demonstrated that increased melanoma ctDNA levels and the appearance of circulating mutations associated with of acquired resistance, provide highly specific, early information of relapse during BRAF targeted therapies [15, 16]. This evidence concerns the gene BRAF and melanoma.